{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:26:27Z","timestamp":1747185987948,"version":"3.40.5"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>To evaluate linagliptin prescribing in type\u00a02 diabetes mellitus patients with different comorbidities, an expanded Japanese post\u2010marketing surveillance also collected baseline data for patients initiating other glucose\u2010lowering drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Patients initiating linagliptin monotherapy were enrolled, then the next patient starting monotherapy with another glucose\u2010lowering drug was enrolled (2012\u20132014). Baseline data were collected and analyzed by the Medical Dictionary for Regulatory Activities system organ class. Analyses were descriptive, and meaningful differences defined as absolute standardized difference &gt;10%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Over 4,200 type 2 diabetes mellitus patients were enrolled. Most system\u2010organ class comorbidities were more common in patients initiating linagliptin versus other glucose\u2010lowering drugs, with meaningful differences observed for metabolism\/nutritional (50.5 <jats:italic>vs<\/jats:italic> 45.5%, respectively), cardiac (12.2 <jats:italic>vs<\/jats:italic> 8.6%, respectively), vascular (56.4 <jats:italic>vs<\/jats:italic> 51.3%, respectively) and renal\/urinary disorders (9.9 <jats:italic>vs<\/jats:italic> 5.7%, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Expanding the linagliptin Japanese post\u2010marketing surveillance revealed linagliptin prescribing to a type\u00a02 diabetes mellitus population with more comorbidities versus other glucose\u2010lowering drugs. Although such preferential prescribing might be expected, as linagliptin requires no dose adjustment or monitoring in renally or hepatically impaired patients, this innovative post\u2010marketing surveillance approach generated important evidence that could only be shown in such a non\u2010randomized comparative study. These data generated insights important for the design and interpretation of observational studies and spontaneous reports, which are key for public health.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.13012","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T17:52:36Z","timestamp":1548265956000},"page":"1246-1253","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preferential prescribing of linagliptin in type\u00a02 diabetes patients in an expanded post\u2010marketing surveillance study in Japan"],"prefix":"10.1111","volume":"10","author":[{"given":"Soulmaz","family":"Fazeli Farsani","sequence":"first","affiliation":[{"name":"Corporate Department Global Epidemiology Boehringer Ingelheim Ingelheim am Rhein Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Biostatistics &amp; Data Science Nippon Boehringer Ingelheim Co., Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Department Nippon Boehringer Ingelheim Co., Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8275-1649","authenticated-orcid":false,"given":"Kimberly G","family":"Brodovicz","sequence":"additional","affiliation":[{"name":"Global Epidemiology Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee B","family":"Bartels","sequence":"additional","affiliation":[{"name":"Hannover Medical School Institute for Epidemiology Social Medicine and Health Systems Research Hannover Germany"},{"name":"BI X GmbH Ingelheim am Rhein Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,3]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"International Diabetes Federation.IDF Western Pacific members: Japan 2015. Available from:https:\/\/www.idf.org\/our-network\/regions-members\/western-pacific\/members\/105-japan.htmlAccessed July 24 2018."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0602-9"},{"key":"e_1_2_8_4_1","unstructured":"Japan Diabetes Society.Treatment Guide for Diabetes 2016\u20132017. Available from:http:\/\/www.fa.kyorin.co.jp\/jds\/uploads\/Treatment_Guide_for_Diabetes_2016-2017.pdfAccessed January 7 2019."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12490"},{"issue":"1","key":"e_1_2_8_6_1","first-page":"S389","article-title":"Use of the Japanese health insurance claims database to assess durability of DPP\u20104 inhibitors in patients with diabetes: comparison with other anti\u2010diabetic drugs","volume":"58","author":"Yabe D","year":"2015","journal-title":"Diabetologia"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-017-0853-8"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2827-3"},{"key":"e_1_2_8_9_1","unstructured":"Boehringer Ingelheim.Tradjenta\u00ae(linagliptin) prescribing information (12\/2016) 2015. Available from:http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Tradjenta\/Tradjenta.pdf?DMW_FORMAT=pdfAccessed November 20 2017."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S59523"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0308-3"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04173.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01458.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1684"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164113507068"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12281"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.06.015"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-60"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.07.002"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.5"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2328w"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006122"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12430"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.je.2016.12.005"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053224"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.je.2016.12.012"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2016-000294"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2016.07.004"},{"key":"e_1_2_8_29_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).Medical Dictionary for Regulatory Activities. MedDRA\u00aetrademark owned by International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on behalf of ICH. Available from:http:\/\/www.meddra.org\/AccessedNovember 20 2017."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3574"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2534-0"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3460-0"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12090"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-015-0133-z"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.489029"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02516.x"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdi.13012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.13012","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T21:12:57Z","timestamp":1694293977000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.13012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/jdi.13012"],"URL":"https:\/\/doi.org\/10.1111\/jdi.13012","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"type":"print","value":"2040-1116"},{"type":"electronic","value":"2040-1124"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"2018-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}